CO2020004301A2 - 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors - Google Patents
1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitorsInfo
- Publication number
- CO2020004301A2 CO2020004301A2 CONC2020/0004301A CO2020004301A CO2020004301A2 CO 2020004301 A2 CO2020004301 A2 CO 2020004301A2 CO 2020004301 A CO2020004301 A CO 2020004301A CO 2020004301 A2 CO2020004301 A2 CO 2020004301A2
- Authority
- CO
- Colombia
- Prior art keywords
- imino
- benzyl
- phenyl
- formula
- protease inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D247/00—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
La invención proporciona un compuesto de Fórmula I: o una sal farmacéuticamente aceptable del mismo como se describe a continuación. La invención también proporciona composiciones farmacéuticas que comprenden un Compuesto de Fórmula I, procesos para preparar Compuestos de Fórmula I, métodos terapéuticos para tratar la proliferación del virus VIH, tratar el SIDA o retrasar la aparición de síntomas de SIDA en un mamífero usando Compuestos de Fórmula I.The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described below. The invention also provides pharmaceutical compositions comprising a Compound of Formula I, processes for preparing Compounds of Formula I, therapeutic methods for treating proliferation of the HIV virus, treating AIDS, or delaying the onset of AIDS symptoms in a mammal using Compounds of Formula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762572243P | 2017-10-13 | 2017-10-13 | |
PCT/US2018/055554 WO2019075291A1 (en) | 2017-10-13 | 2018-10-12 | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020004301A2 true CO2020004301A2 (en) | 2020-05-15 |
Family
ID=64051787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0004301A CO2020004301A2 (en) | 2017-10-13 | 2020-04-08 | 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors |
Country Status (21)
Country | Link |
---|---|
US (2) | US10774053B2 (en) |
EP (1) | EP3694846A1 (en) |
JP (2) | JP7136892B2 (en) |
KR (1) | KR102515284B1 (en) |
CN (1) | CN111212832B (en) |
AR (1) | AR113765A1 (en) |
AU (1) | AU2018347541C1 (en) |
BR (1) | BR102018071016A2 (en) |
CA (1) | CA3076761C (en) |
CL (1) | CL2020000886A1 (en) |
CO (1) | CO2020004301A2 (en) |
CR (1) | CR20200149A (en) |
EA (1) | EA202090530A1 (en) |
IL (1) | IL273842A (en) |
JO (1) | JOP20180092A1 (en) |
MX (1) | MX2020003430A (en) |
PE (1) | PE20201497A1 (en) |
PH (1) | PH12020550256A1 (en) |
SG (1) | SG11202002235XA (en) |
TW (2) | TWI697491B (en) |
WO (1) | WO2019075291A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102498819B1 (en) | 2017-04-11 | 2023-02-10 | 미쓰이가가쿠 아그로 가부시키가이샤 | Pyridone compound and agricultural and horticultural fungicide containing it as an active ingredient |
TW202104210A (en) * | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv protease inhibitors |
US20200347036A1 (en) * | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
WO2023074936A1 (en) * | 2021-10-27 | 2023-05-04 | 주식회사 오토텍바이오 | Bifunctional compound using ubr box domain-binding ligand |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
TW202337439A (en) | 2021-12-03 | 2023-10-01 | 美商基利科學股份有限公司 | Therapeutic compounds for hiv virus infection |
TW202400165A (en) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
CN115260167A (en) * | 2022-08-01 | 2022-11-01 | 陕西盘龙药业集团股份有限公司 | 3-tetrazolylmethyl-1, 3, 5-triazine-2, 4-diketone compound and preparation method and application thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
GB0016787D0 (en) | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
EA007184B1 (en) | 2001-04-10 | 2006-08-25 | Пфайзер Инк. | Pyrazole derivatives for treating hiv |
NZ542342A (en) | 2003-04-25 | 2009-05-31 | Gilead Sciences Inc | Antiviral phosphonate analogs |
US7763609B2 (en) * | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP1699455B1 (en) * | 2003-12-15 | 2013-05-08 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
DOP2005000123A (en) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | CETP INHIBITORS |
AU2005330489B2 (en) | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
WO2007059195A1 (en) | 2005-11-14 | 2007-05-24 | University Of Southern California | Integrin-binding small molecules |
ATE516016T1 (en) | 2005-12-05 | 2011-07-15 | Merck Sharp & Dohme | SELF-EMULSIFYING FORMULATIONS OF CETP INHIBITORS |
US7910592B2 (en) | 2005-12-30 | 2011-03-22 | Merck Sharp & Dohme Corp. | CETP inhibitors |
JP5199121B2 (en) | 2005-12-30 | 2013-05-15 | メルク・シャープ・エンド・ドーム・コーポレイション | CETP inhibitor |
KR20140107671A (en) | 2005-12-30 | 2014-09-04 | 머크 샤프 앤드 돔 코포레이션 | 1,3-Oxazolidin-2-one derivatives useful as CETP inhibitors |
US8030359B2 (en) | 2006-02-09 | 2011-10-04 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
JP5285709B2 (en) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | Human immunodeficiency virus replication inhibitor |
WO2009070305A1 (en) | 2007-11-26 | 2009-06-04 | Eisai E & D Management Co., Ltd. | Method of making imidazoazepinone compounds |
KR101787309B1 (en) | 2008-12-09 | 2017-10-18 | 길리애드 사이언시즈, 인코포레이티드 | Modulators of toll-like receptors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
WO2011133719A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
AU2011274323B2 (en) | 2010-07-02 | 2015-08-06 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as HIV antiviral compounds |
US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (en) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | Antiviral compound |
US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
CA2850881C (en) | 2012-04-20 | 2021-02-16 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
US9216996B2 (en) | 2012-12-21 | 2015-12-22 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
JP6320039B2 (en) | 2012-12-27 | 2018-05-09 | 日本たばこ産業株式会社 | Substituted spiropyrido [1,2-a] pyrazine derivatives and their pharmaceutical use as HIV integrase inhibitors |
EP2958897B1 (en) | 2013-02-19 | 2019-01-09 | Senomyx, Inc. | Compounds useful as modulators of trpm8 |
WO2014150981A1 (en) | 2013-03-15 | 2014-09-25 | Elan Pharmaceuticals, Llc | Inhibitors of lrrk2 kinase activity |
NZ712479A (en) | 2013-03-15 | 2019-01-25 | Univ Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
US20190046507A1 (en) | 2016-02-18 | 2019-02-14 | Merck Sharp & Dohme Corp. | Compounds for the treatment of malaria |
US10696639B2 (en) | 2016-12-06 | 2020-06-30 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as HIV protease inhibitors |
WO2018118829A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as hiv protease inhibitors |
-
2017
- 2017-10-13 JO JOP/2018/0092A patent/JOP20180092A1/en unknown
-
2018
- 2018-10-11 BR BR102018071016-8A patent/BR102018071016A2/en not_active Application Discontinuation
- 2018-10-12 AR ARP180102964A patent/AR113765A1/en unknown
- 2018-10-12 TW TW107135975A patent/TWI697491B/en active
- 2018-10-12 SG SG11202002235XA patent/SG11202002235XA/en unknown
- 2018-10-12 US US16/158,446 patent/US10774053B2/en active Active
- 2018-10-12 MX MX2020003430A patent/MX2020003430A/en unknown
- 2018-10-12 KR KR1020207013543A patent/KR102515284B1/en active IP Right Grant
- 2018-10-12 AU AU2018347541A patent/AU2018347541C1/en active Active
- 2018-10-12 EA EA202090530A patent/EA202090530A1/en unknown
- 2018-10-12 TW TW109119188A patent/TW202045490A/en unknown
- 2018-10-12 PE PE2020000525A patent/PE20201497A1/en unknown
- 2018-10-12 CN CN201880066480.8A patent/CN111212832B/en active Active
- 2018-10-12 WO PCT/US2018/055554 patent/WO2019075291A1/en unknown
- 2018-10-12 EP EP18796285.7A patent/EP3694846A1/en active Pending
- 2018-10-12 JP JP2020520483A patent/JP7136892B2/en active Active
- 2018-10-12 CA CA3076761A patent/CA3076761C/en active Active
- 2018-10-12 CR CR20200149A patent/CR20200149A/en unknown
-
2020
- 2020-04-01 CL CL2020000886A patent/CL2020000886A1/en unknown
- 2020-04-06 IL IL273842A patent/IL273842A/en unknown
- 2020-04-08 CO CONC2020/0004301A patent/CO2020004301A2/en unknown
- 2020-04-13 PH PH12020550256A patent/PH12020550256A1/en unknown
- 2020-07-09 US US16/925,096 patent/US11352329B2/en active Active
-
2021
- 2021-08-03 JP JP2021127542A patent/JP2021178852A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2019075291A1 (en) | 2019-04-18 |
AU2018347541C1 (en) | 2022-01-13 |
PE20201497A1 (en) | 2020-12-29 |
MX2020003430A (en) | 2020-07-29 |
CA3076761C (en) | 2024-03-26 |
CA3076761A1 (en) | 2019-04-18 |
CN111212832B (en) | 2023-09-15 |
PH12020550256A1 (en) | 2021-03-01 |
KR102515284B1 (en) | 2023-03-31 |
IL273842A (en) | 2020-05-31 |
AU2018347541B2 (en) | 2021-06-17 |
SG11202002235XA (en) | 2020-04-29 |
US11352329B2 (en) | 2022-06-07 |
CR20200149A (en) | 2020-05-22 |
TWI697491B (en) | 2020-07-01 |
TW201927766A (en) | 2019-07-16 |
CN111212832A (en) | 2020-05-29 |
EA202090530A1 (en) | 2020-10-06 |
JOP20180092A1 (en) | 2019-04-13 |
KR20200071098A (en) | 2020-06-18 |
AR113765A1 (en) | 2020-06-10 |
JP2020536911A (en) | 2020-12-17 |
TW202045490A (en) | 2020-12-16 |
CL2020000886A1 (en) | 2020-10-09 |
US10774053B2 (en) | 2020-09-15 |
JP7136892B2 (en) | 2022-09-13 |
US20190210978A1 (en) | 2019-07-11 |
EP3694846A1 (en) | 2020-08-19 |
JP2021178852A (en) | 2021-11-18 |
AU2018347541A1 (en) | 2020-04-16 |
BR102018071016A2 (en) | 2019-05-07 |
US20210078959A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020004301A2 (en) | 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
DOP2019000201A (en) | HIV INHIBITING COMPOUNDS | |
AR118707A1 (en) | HIV PROTEASE INHIBITORS | |
UY37710A (en) | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
ECSP22023220A (en) | MONO OR DISUBSTITUTED INDOL DERIVATIVES AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
DOP2020000102A (en) | HELPFUL COMPOUNDS TO INHIBIT CDK7 | |
NI201700020A (en) | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | |
CO6660497A2 (en) | Derivatives of nft-2-ylacetic acid to treat AIDS | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
UY37182A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE | |
PH12018502026A1 (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
CO2018008421A2 (en) | Indoline derivatives substituted as inhibitors of dengue viral replication | |
CL2017001822A1 (en) | Mono or disubstituted indole derivatives as inhibitors of dengue virus replication | |
EA201692487A1 (en) | PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | |
CR20190446A (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
EA201692249A1 (en) | PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | |
CO2018009559A2 (en) | Indole derivatives substituted as inhibitors of dengue viral replication | |
UY36339A (en) | MONKEY OR DISABLED INDOLES AS INHIBITORS OF THE DENGUE VIRUS REPLICATION | |
UY37742A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
CO2021005532A2 (en) | Quinoline derivatives as inhibitors of integrin alpha4beta7 | |
EA201692265A1 (en) | PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | |
MX2020003732A (en) | Fused ring derivative as a. | |
EA202091169A1 (en) | SMAC MIMETICS USED AS IAP INHIBITORS AND THEIR APPLICATION | |
EA201792265A1 (en) | METHODS OF TREATING CARDIOVASCULAR DISEASES | |
EA202091668A2 (en) | HUMAN PLASMA CALLICREIN INHIBITORS |